Lineage Cell Therapeutics, Inc. (LCTX) fundamentals score
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. Certain diseases and medical events can arise from the loss of critical cellular activity and lead to devastating or difficult-to-treat conditions or impairments.
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NYSE
Overall: 4.5 out of 10, Weak long-term fundamentals
- Growth: 3.2/10
- Profitability: 3.3/10
- Financial health: 6.1/10
- Earnings quality: 7.0/10
- Valuation: 3.9/10
Scores are calculated from Lineage Cell Therapeutics, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10